NasdaqGS:AMGNBiotechs
Amgen (AMGN) Could Be 45% Below Fair Value As Court Blocks Enbrel Price Cap
Amgen (AMGN) is back in focus after a federal judge blocked Colorado’s proposed 70% price cap on Enbrel, which removed an immediate regulatory threat to one of the company’s key revenue drivers.
See our latest analysis for Amgen.
The court decision has come on top of an already strong run in Amgen’s stock, with a 1-day share price return of 3.55% and a year to date share price return of 14.20%, while total shareholder return sits at 29.22% over one year and 87.63% over three years. This...